Extensive-Stage Small-Cell Lung Cancer: Current Landscape and Future Prospects

References

• Toyoda Y, Nakayama T, Ioka A, et al. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol. 2008;38(8):534–539. doi:10.1093/jjco/hyn072
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725–737. doi:10.1038/nrc.2017.87
   PubMed Web of Science ®Google Scholar
• Simon GR, Wagner H. Small cell lung cancer. Chest. 2003;123(1 Suppl):259s–271s. doi:10.1378/chest.123.1_suppl.259s
   PubMed Web of Science ®Google Scholar
• Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 1985;45(6):2913–2923.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 1985;45(6):2924–2930.
   PubMed Web of Science ®Google Scholar
• Jiang T, Collins BJ, Jin N, et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 2009;69(3):845–854. doi:10.1158/0008-5472.Can-08-2762
   PubMed Web of Science ®Google Scholar
• Poirier JT, Dobromilskaya I, Moriarty WF, et al. Selective tropism of Seneca valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst. 2013;105(14):1059–1065. doi:10.1093/jnci/djt130
   PubMedGoogle Scholar
• Borromeo MD, Savage TK, Kollipara RK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 2016;16(5):1259–1272. doi:10.1016/j.celrep.2016.06.081
   PubMed Web of Science ®Google Scholar
• Huang YH, Klingbeil O, He XY, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018;32(13–14):915–928. doi:10.1101/gad.314815.118
   PubMed Web of Science ®Google Scholar
• Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289–297. doi:10.1038/s41568-019-0133-9
   PubMed Web of Science ®Google Scholar
• Baine MK, Hsieh MS, Lai WV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15(12):1823–1835. doi:10.1016/j.jtho.2020.09.009
   PubMed Web of Science ®Google Scholar
• Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346–360.e7. doi:10.1016/j.ccell.2020.12.014
   PubMed Web of Science ®Google Scholar
• Thiel G, Ekici M, Rössler OG. RE-1 silencing transcription factor (REST): a regulator of neuronal development and neuronal/endocrine function. Cell Tissue Res. 2015;359(1):99–109. doi:10.1007/s00441-014-1963-0
   PubMed Web of Science ®Google Scholar
• Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–1116. doi:10.1038/ng.2405
   PubMed Web of Science ®Google Scholar
• Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–1110. doi:10.1038/ng.2396
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. doi:10.1038/nature14664
   PubMed Web of Science ®Google Scholar
• Lee JK, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol. 2017;35(26):3065–3074. doi:10.1200/jco.2016.71.9096
   PubMed Web of Science ®Google Scholar
• Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83. doi:10.1126/science.aah4199
   PubMed Web of Science ®Google Scholar
• Patel AS, Yoo S, Kong R, et al. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer. Sci Adv. 2021;7(5). doi:10.1126/sciadv.abc2578
   Web of Science ®Google Scholar
• Ireland AS, Micinski AM, Kastner DW, et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38(1):60–78.e12. doi:10.1016/j.ccell.2020.05.001
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Fernandez-Cuesta L, Damiola F, et al. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Transl Lung Cancer Res. 2020;9(5):2233–2244. doi:10.21037/tlcr-20-269.
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–1816. doi:10.1093/annonc/mdq036
   PubMed Web of Science ®Google Scholar
• Lima JP, Dos Santos LV, Sasse EC, et al. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol. 2010;5(12):1986–1993. doi:10.1097/JTO.0b013e3181f2451c
   PubMed Web of Science ®Google Scholar
• Han D, Wang G, Sun L, et al. Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: a meta-analysis. Eur J Cancer Care. 2017;26(6):e12723. doi:10.1111/ecc.12723
   Web of Science ®Google Scholar
• Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010;5(6):867–873. doi:10.1097/jto.0b013e3181d95c87
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91. doi:10.1056/NEJMoa003034
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2038–2043. doi:10.1200/jco.2005.04.8595
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530–2535. doi:10.1200/jco.2008.20.1061
   PubMed Web of Science ®Google Scholar
• Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–630. doi:10.1200/jco.20.01055
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/s0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65. doi:10.1016/s1470-2045(20)30539-8
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–747. doi:10.1016/s1470-2045(22)00224-8
   PubMed Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–2379. doi:10.1200/jco.20.00793
   PubMed Web of Science ®Google Scholar
• Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223–1232. doi:10.1001/jama.2022.16464
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83. doi:10.1093/annonc/mds213
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3748. doi:10.1200/jco.2016.67.6601
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: checkMate 451. J Clin Oncol. 2021;39(12):1349–1359. doi:10.1200/jco.20.02212
   PubMed Web of Science ®Google Scholar
• Asao T, Watanabe S, Tanaka T, et al. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol. BMC Cancer. 2022;22(1):1135. doi:10.1186/s12885-022-10222-1
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33(5):853–861.e4. doi:10.1016/j.ccell.2018.04.001
   PubMed Web of Science ®Google Scholar
• Federico L, McGrail DJ, Bentebibel SE, et al. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2022;33(1):42–56. doi:10.1016/j.annonc.2021.09.021
   PubMed Web of Science ®Google Scholar
• Iams WT, Shiuan E, Meador CB, et al. Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes. J Thorac Oncol. 2019;14(11):1970–1981. doi:10.1016/j.jtho.2019.05.042
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441–5447. doi:10.1200/jco.2006.06.5821
   PubMed Web of Science ®Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–667. doi:10.1200/jco.1999.17.2.658
   PubMed Web of Science ®Google Scholar
• Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26(33):5401–5406. doi:10.1200/jco.2008.18.1974
   PubMed Web of Science ®Google Scholar
• Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011;29(3):287–293. doi:10.1200/jco.2010.29.8851
   PubMed Web of Science ®Google Scholar
• von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–4019. doi:10.1200/jco.2013.54.5392
   PubMed Web of Science ®Google Scholar
• Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(8):1147–1157. doi:10.1016/s1470-2045(16)30104-8
   PubMed Web of Science ®Google Scholar
• Baize N, Monnet I, Greillier L, et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1224–1233. doi:10.1016/s1470-2045(20)30461-7
   PubMed Web of Science ®Google Scholar
• Uematsu S, Kitazono S, Tanaka H, et al. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: a retrospective multicenter study (TOPGAN 2021-01). Thorac Cancer. 2023;14(2):168–176. doi:10.1111/1759-7714.14729
   PubMed Web of Science ®Google Scholar
• Imai H, Nagai Y, Minemura H, et al. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. Invest New Drugs. 2022;40(5):1066–1079. doi:10.1007/s10637-022-01269-9
   PubMed Web of Science ®Google Scholar
• Kushiro K, Watanabe S, Goto Y, et al. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients. Transl Lung Cancer Res. 2022;11(9):1858–1865. doi:10.21037/tlcr-22-225
   PubMed Web of Science ®Google Scholar
• Kondo R, Watanabe S, Shoji S, et al. A phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology. 2018;94(4):223–232. doi:10.1159/000486622
   PubMed Web of Science ®Google Scholar
• Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645–654. doi:10.1016/s1470-2045(20)30068-1
   PubMed Web of Science ®Google Scholar
• Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, et al. ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol. 2019;15(3):231–239. doi:10.2217/fon-2018-0597
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895. doi:10.1016/s1470-2045(16)30098-5
   PubMed Web of Science ®Google Scholar
• Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: checkMate 032. J Thorac Oncol. 2019;14(2):237–244. doi:10.1016/j.jtho.2018.10.003
   PubMed Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol. 2020;15(4):618–627. doi:10.1016/j.jtho.2019.12.109
   PubMed Web of Science ®Google Scholar
• Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: checkMate 331(☆). Ann Oncol. 2021;32(5):631–641. doi:10.1016/j.annonc.2021.01.071
   PubMed Web of Science ®Google Scholar
• Brazel D, Ou SI, Nagasaka M. Tiragolumab (Anti-TIGIT) in SCLC: skyscraper-02, a towering inferno. Lung Cancer. 2023;14:1–9. doi:10.2147/lctt.S379389
   PubMed Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798–811. doi:10.1158/2159-8290.Cd-12-0112
   PubMed Web of Science ®Google Scholar
• Ai X, Pan Y, Shi J, et al. Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, phase 3 study. J Thorac Oncol. 2021;16(8):1403–1414. doi:10.1016/j.jtho.2021.04.001
   PubMed Web of Science ®Google Scholar
• Woll P, Gaunt P, Danson S, et al. Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): a randomised, double-blind, placebo-controlled phase II trial. Lung Cancer. 2022;171:26–33. doi:10.1016/j.lungcan.2022.07.007
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36(23):2386–2394. doi:10.1200/jco.2018.77.7672
   PubMed Web of Science ®Google Scholar
• Miao J, Reckamp KL, Gay CM, et al. SWOG S1929: phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2023;41(16_suppl):8504. doi:10.1200/JCO.2023.41.16_suppl.8504
   Web of Science ®Google Scholar
• Owonikoko TK, Dahlberg SE, Sica GL, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37(3):222–229. doi:10.1200/jco.18.00264
   PubMed Web of Science ®Google Scholar
• Thomas A, Vilimas R, Trindade C, et al. Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a Phase II study. J Thorac Oncol. 2019;14(8):1447–1457. doi:10.1016/j.jtho.2019.04.026
   PubMed Web of Science ®Google Scholar
• Zhang C, Leighl NB, Wu YL, et al. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019;12(1):45. doi:10.1186/s13045-019-0731-8
   PubMedGoogle Scholar
• Blackhall F, Jao K, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16(9):1547–1558. doi:10.1016/j.jtho.2021.02.009
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;41(16):2893–2903. doi:10.1200/jco.22.02823
   PubMed Web of Science ®Google Scholar
• Thomas A, Takahashi N, Rajapakse VN, et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell. 2021;39(4):566–579.e7. doi:10.1016/j.ccell.2021.02.014
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18(11):3163–3169. doi:10.1158/1078-0432.Ccr-11-3090
   PubMed Web of Science ®Google Scholar
• Lochmann TL, Floros KV, Naseri M, et al. Venetoclax is effective in small-cell lung cancers with high BCL-2 expression. Clin Cancer Res. 2018;24(2):360–369. doi:10.1158/1078-0432.Ccr-17-1606
   PubMed Web of Science ®Google Scholar
• Augert A, Eastwood E, Ibrahim AH, et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal. 2019;12(567). doi:10.1126/scisignal.aau2922
   PubMed Web of Science ®Google Scholar
• Mollaoglu G, Guthrie MR, Böhm S, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31(2):270–285. doi:10.1016/j.ccell.2016.12.005
   PubMed Web of Science ®Google Scholar
• Sen T, Tong P, Stewart CA, et al. CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib. Cancer Res. 2017;77(14):3870–3884. doi:10.1158/0008-5472.Can-16-3409
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Spigel DR, Chen Y, et al. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. Cancer. 2022;128(9):1801–1811. doi:10.1002/cncr.34123
   PubMed Web of Science ®Google Scholar
• Pujol JL, Lavole A, Quoix E, et al. Randomized Phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Ann Oncol. 2015;26(5):908–914. doi:10.1093/annonc/mdv065
   PubMed Web of Science ®Google Scholar
• Tiseo M, Boni L, Ambrosio F, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35(12):1281–1287. doi:10.1200/jco.2016.69.4844
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li K, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer. 2021;125(3):366–371. doi:10.1038/s41416-021-01356-3
   PubMed Web of Science ®Google Scholar